5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hepatotoxicity O
: O
Fatal O
hepatotoxicity O
occurred O
in O
0.1 O
% O
of O
patients O
. O

Monitor O
with O
periodic O
liver O
testing O
. O

Temporarily O
suspend O
, O
dose O
reduce O
, O
or O
permanently O
discontinue O
XALKORI O
. O

( O
5.1 O
) O
* O
Interstitial O
Lung O
Disease O
( O
ILD O
) O
/Pneumonitis O
: O
Occurred O
in O
2.9 O
% O
of O
patients O
. O

Permanently O
discontinue O
in O
patients O
with O
ILD/pneumonitis O
. O

( O
5.2 O
) O
* O
QT O
Interval O
Prolongation O
: O
Occurred O
in O
2.1 O
% O
of O
patients O
. O

Monitor O
electrocardiograms O
and O
electrolytes O
in O
patients O
who O
have O
a O
history O
of O
or O
predisposition O
for O
QTc O
prolongation O
, O
or O
who O
are O
taking O
medications O
that O
prolong O
QT O
. O

Temporarily O
suspend O
, O
dose O
reduce O
, O
or O
permanently O
discontinue O
XALKORI O
. O

( O
5.3 O
) O
* O
Bradycardia O
: O
XALKORI O
can O
cause O
bradycardia O
. O

Monitor O
heart O
rate O
and O
blood O
pressure O
regularly O
. O

Temporarily O
suspend O
, O
dose O
reduce O
, O
or O
permanently O
discontinue O
XALKORI O
. O

( O
5.4 O
) O
* O
Severe O
Visual O
Loss O
: O
Reported O
in O
0.2 O
% O
of O
patients O
. O

Discontinue O
XALKORI O
in O
patients O
with O
severe O
visual O
loss O
. O

Perform O
an O
ophthalmological O
evaluation O
. O

( O
5.5 O
) O
* O
Embryo-Fetal O
Toxicity O
: O
Can O
cause O
fetal O
harm O
. O

Advise O
females O
of O
reproductive O
potential O
of O
the O
potential O
risk O
to O
a O
fetus O
and O
use O
of O
effective O
contraception O
. O

( O
5.6 O
, O
8.1 O
, O
8.3 O
) O
5.1 O
Hepatotoxicity B-OSE_Labeled_AE
Drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
hepatotoxicity I-OSE_Labeled_AE
with O
fatal B-NonOSE_AE
outcome O
occurred O
in O
2 O
( O
0.1 O
% O
) O
of O
the O
1719 O
patients O
treated O
with O
XALKORI O
across O
clinical O
trials O
. O

Concurrent O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
alanine I-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
or O
aspartate O
aminotransferase O
( O
AST O
) O
greater O
than O
or O
equal O
to O
3 O
times O
the O
upper O
limit O
of O
normal O
( O
ULN O
) O
and O
total B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
or I-OSE_Labeled_AE
equal I-OSE_Labeled_AE
to I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
, O
with O
normal O
alkaline O
phosphatase O
, O
occurred O
in O
10 O
patients O
( O
< O
1 O
% O
) O
treated O
with O
XALKORI O
. O

Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT O
or O
AST I-OSE_Labeled_AE
greater O
than O
5 O
times O
the O
ULN O
occurred O
in O
187 O
( O
11.2 O
% O
) O
and O
95 O
( O
5.7 O
% O
) O
patients O
, O
respectively O
. O

Seventeen O
patients O
( O
1.0 O
% O
) O
required O
permanent O
discontinuation O
due O
to O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
. O

Transaminase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
generally O
occurred O
within O
the O
first O
2 O
months O
of O
treatment O
. O

Monitor O
liver O
function O
tests O
, O
including O
ALT O
, O
AST O
, O
and O
total O
bilirubin O
, O
every O
2 O
weeks O
during O
the O
first O
2 O
months O
of O
treatment O
, O
then O
once O
a O
month O
, O
and O
as O
clinically O
indicated O
, O
with O
more O
frequent O
repeat O
testing O
for O
increased B-NonOSE_AE
liver I-NonOSE_AE
transaminases I-NonOSE_AE
, O
alkaline O
phosphatase O
, O
or O
total O
bilirubin O
in O
patients O
who O
develop O
transaminase B-NonOSE_AE
elevations I-NonOSE_AE
. O

Temporarily O
suspend O
, O
dose O
reduce O
, O
or O
permanently O
discontinue O
XALKORI O
as O
described O
in O
Table O
2 O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.2 O
Interstitial O
Lung O
Disease O
( O
Pneumonitis O
) O
Severe O
, O
life-threatening O
, O
or O
fatal O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ILD I-OSE_Labeled_AE
) O
/ O
pneumonitis B-OSE_Labeled_AE
can O
occur O
in O
patients O
treated O
with O
XALKORI O
. O

Across O
clinical O
trials O
( O
n=1719 O
) O
, O
50 O
XALKORI-treated O
patients O
( O
2.9 O
% O
) O
had O
ILD B-OSE_Labeled_AE
of O
any O
grade O
, O
18 O
patients O
( O
1.0 O
% O
) O
had O
Grade O
3 O
or O
4 O
ILD B-OSE_Labeled_AE
, O
and O
8 O
patients O
( O
0.5 O
% O
) O
had O
fatal B-NonOSE_AE
ILD B-OSE_Labeled_AE
. O

Interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
generally O
occurred O
within O
3 O
months O
after O
the O
initiation O
of O
XALKORI O
. O

Monitor O
patients O
for O
pulmonary B-NonOSE_AE
symptoms I-NonOSE_AE
indicative O
of O
ILD B-NonOSE_AE
/ O
pneumonitis B-NonOSE_AE
. O

Exclude O
other O
potential O
causes O
of O
ILD B-NonOSE_AE
/ O
pneumonitis B-NonOSE_AE
, O
and O
permanently O
discontinue O
XALKORI O
in O
patients O
diagnosed O
with O
drug B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
ILD I-NonOSE_AE
/ O
pneumonitis B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.3 O
QT O
Interval O
Prolongation O
QTc B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
can O
occur O
in O
patients O
treated O
with O
XALKORI O
. O

Across O
clinical O
trials O
, O
34 O
of O
1616 O
patients O
( O
2.1 O
% O
) O
had O
QTcF B-OSE_Labeled_AE
( O
corrected O
QT O
for O
heart O
rate O
by O
the O
Fridericia O
method O
) O
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
or I-OSE_Labeled_AE
equal I-OSE_Labeled_AE
to I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
ms I-OSE_Labeled_AE
and O
79 O
of O
1582 O
patients O
( O
5.0 O
% O
) O
had O
an O
increase B-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
QTcF I-OSE_Labeled_AE
greater O
than O
or O
equal O
to O
60 O
ms O
by O
automated O
machine-read O
evaluation O
of O
ECGs O
. O

Avoid O
use O
of O
XALKORI O
in O
patients O
with O
congenital B-Not_AE_Candidate
long I-Not_AE_Candidate
QT I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
. O

Monitor O
ECGs O
and O
electrolytes O
in O
patients O
with O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
bradyarrhythmias B-Not_AE_Candidate
, O
electrolyte B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
or O
who O
are O
taking O
medications O
that O
are O
known O
to O
prolong B-NonOSE_AE
the I-NonOSE_AE
QT I-NonOSE_AE
interval I-NonOSE_AE
. O

Permanently O
discontinue O
XALKORI O
in O
patients O
who O
develop O
QTc B-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
ms I-NonOSE_AE
or O
greater O
than O
or O
equal O
to O
60 O
ms O
change O
from O
baseline O
with O
Torsade B-NonOSE_AE
de I-NonOSE_AE
pointes I-NonOSE_AE
or O
polymorphic B-NonOSE_AE
ventricular I-NonOSE_AE
tachycardia I-NonOSE_AE
or O
signs/symptoms O
of O
serious B-NonOSE_AE
arrhythmia I-NonOSE_AE
. O

Withhold O
XALKORI O
in O
patients O
who O
develop O
QTc B-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
ms I-NonOSE_AE
on O
at O
least O
2 O
separate O
ECGs O
until O
recovery O
to O
a O
QTc O
less O
than O
or O
equal O
to O
480 O
ms O
, O
then O
resume O
XALKORI O
at O
a O
reduced O
dose O
as O
described O
in O
Table O
2 O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

5.4 O
Bradycardia O
Symptomatic O
bradycardia B-OSE_Labeled_AE
can O
occur O
in O
patients O
receiving O
XALKORI O
. O

Across O
clinical O
trials O
, O
bradycardia B-OSE_Labeled_AE
occurred O
in O
219 O
( O
12.7 O
% O
) O
of O
1719 O
patients O
treated O
with O
XALKORI O
. O

Grade O
3 O
syncope B-OSE_Labeled_AE
occurred O
in O
2.4 O
% O
of O
XALKORI-treated O
patients O
and O
in O
0.6 O
% O
of O
the O
chemotherapy-treated O
patients O
. O

Avoid O
using O
XALKORI O
in O
combination O
with O
other O
agents O
known O
to O
cause O
bradycardia B-NonOSE_AE
( O
e.g. O
, O
beta-blockers O
, O
non-dihydropyridine O
calcium O
channel O
blockers O
, O
clonidine O
, O
and O
digoxin O
) O
to O
the O
extent O
possible O
. O

Monitor O
heart O
rate O
and O
blood O
pressure O
regularly O
. O

In O
cases O
of O
symptomatic B-NonOSE_AE
bradycardia I-NonOSE_AE
that O
is O
not O
life-threatening O
, O
hold O
XALKORI O
until O
recovery O
to O
asymptomatic O
bradycardia B-NonOSE_AE
or O
to O
a O
heart O
rate O
of O
60 O
bpm O
or O
above O
, O
re-evaluate O
the O
use O
of O
concomitant O
medications O
, O
and O
adjust O
the O
dose O
of O
XALKORI O
. O

Permanently O
discontinue O
for O
life-threatening O
bradycardia B-NonOSE_AE
due O
to O
XALKORI O
; O
however O
, O
if O
associated O
with O
concomitant O
medications O
known O
to O
cause O
bradycardia B-NonOSE_AE
or O
hypotension B-NonOSE_AE
, O
hold O
XALKORI O
until O
recovery O
to O
asymptomatic O
bradycardia B-NonOSE_AE
or O
to O
a O
heart O
rate O
of O
60 O
bpm O
or O
above O
, O
and O
if O
concomitant O
medications O
can O
be O
adjusted O
or O
discontinued O
, O
restart O
XALKORI O
at O
250 O
mg O
once O
daily O
with O
frequent O
monitoring O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.5 O
Severe O
Visual O
Loss O
Across O
all O
clinical O
trials O
, O
the O
incidence O
of O
Grade O
4 O
visual B-OSE_Labeled_AE
field I-OSE_Labeled_AE
defect I-OSE_Labeled_AE
with O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
was O
0.2 O
% O
( O
4/1719 O
) O
. O

Optic B-OSE_Labeled_AE
atrophy I-OSE_Labeled_AE
and O
optic B-OSE_Labeled_AE
nerve I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
have O
been O
reported O
as O
potential O
causes O
of O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
. O

Discontinue O
XALKORI O
in O
patients O
with O
new O
onset O
of O
severe O
visual B-NonOSE_AE
loss I-NonOSE_AE
( O
best O
corrected O
vision O
less O
than O
20/200 O
in O
one O
or O
both O
eyes O
) O
. O

Perform O
an O
ophthalmological O
evaluation O
consisting O
of O
best O
corrected O
visual O
acuity O
, O
retinal O
photographs O
, O
visual O
fields O
, O
optical O
coherence O
tomography O
( O
OCT O
) O
and O
other O
evaluations O
as O
appropriate O
for O
new O
onset O
of O
severe O
visual B-NonOSE_AE
loss I-NonOSE_AE
. O

There O
is O
insufficient O
information O
to O
characterize O
the O
risks O
of O
resumption O
of O
XALKORI O
in O
patients O
with O
a O
severe O
visual B-NonOSE_AE
loss I-NonOSE_AE
; O
a O
decision O
to O
resume O
XALKORI O
should O
consider O
the O
potential O
benefits O
to O
the O
patient O
. O

5.6 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Based O
on O
its O
mechanism O
of O
action O
, O
XALKORI O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

In O
animal O
reproduction O
studies O
, O
oral O
administration O
of O
crizotinib O
in O
pregnant B-NonOSE_AE
rats O
during O
organogenesis O
at O
exposures O
similar O
to O
those O
observed O
with O
the O
maximum O
recommended O
human O
dose O
resulted O
in O
embryotoxicity B-NonOSE_AE
and O
fetotoxicity B-NonOSE_AE
. O

Advise O
pregnant B-Not_AE_Candidate
women O
of O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Advise O
females O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
treatment O
with O
XALKORI O
and O
for O
at O
least O
45 O
days O
following O
the O
final O
dose O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.3 O
) O
] O
. O

Advise O
male O
patients O
with O
female O
partners O
of O
reproductive O
potential O
to O
use O
condoms O
during O
treatment O
with O
XALKORI O
and O
for O
at O
least O
90 O
days O
after O
the O
final O
dose O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

